Up-to-date List of Theraflu Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Theraflu Medical Research Studies

RankStatusStudy
1 Unknown  Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients
Conditions: Pain;   Opioid Tolerance;   Analgesia Tolerance
Interventions: Drug: Dextromethorphan;   Drug: Placebo
Outcome Measure: Effect of N-methyl D-aspartate (NMDA) receptor antagonist Dextromethorphan on Opiods analgesia and tolerance in Pediatric Intensive Care Unit Patients
2 Recruiting Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo
Condition: Cough Reflex Sensitivity
Interventions: Drug: Phenylephrine;   Drug: Diphenhydramine;   Drug: Dextromethorphan
Outcome Measure: change in cough reflex sensitivity to capsaicin
3 Recruiting Placebo Controlled Trial of Dextromethorphan in Rett Syndrome
Condition: Rett Syndrome
Interventions: Drug: dextromethorphan;   Drug: placebo
Outcome Measures: Neuropsychological test (Mullen Scales of Early Learning).;   Behavior scale: Vineland Adaptive Behavior Scales (VABS);   Behavior and temperament dysregulation measured by the Ghuman-Folstein Screen for Social Interaction (SSI);.
4 Recruiting Study of NMDA Antagonists and Neuropathic Pain
Condition: Neuropathic Pain
Interventions: Drug: Dextromethorphan (drug used like antitussive);   Drug: Memantine (drug used in Alzheimer's disease);   Drug: Placebo (lactose)
Outcome Measures: Measure of pain by numerical scale;   Patient Global Impression if Change (PGIC);   Leed's slip questionnaire;   Questionnaire of quality of life SF 36;   DN4 scale;   Neuropathic Pain Symptoms Inventory (NPSI);   Saint-Antoine questionnaire (QDSA);   HAD scale;   Questionnaire of identification of pain (QCD);   Evaluation of cognitive impact (Cantab, Cambridge)
5 Available Dextromethorphan Added on for the Patients With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Dextromethorphan
Outcome Measure:
6 Recruiting Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS), part 3;   UDysRS, part 4;   Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III-motor score;   Bradykinesia;   MDS-UPDRS part I, II, and IV;   UDysRS part 1 and 2;   PD Motor Diary
7 Not yet recruiting Histamine Glutamate Antagonism in Stroke
Conditions: Acute Cerebrovascular Accident;   Cerebral Edema
Interventions: Drug: Diphenhydramine;   Drug: Pantoprazole;   Drug: Famotidine;   Drug: Dextromethorphan
Outcome Measures: Modified Rankin Score;   National Institutes of Health Stroke Severity (NIHSS) Scale;   Neurological examination of the subject;   All cause mortality data
8 Recruiting Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Conditions: Agitation;   Alzheimer's Disease
Interventions: Drug: AVP-923 (dextromethorphan/quinidine);   Drug: Placebo
Outcome Measures: Neuropsychiatric Inventory (NPI);   Safety and Tolerability;   ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Rating);   QoL-AD (Quality of Life - Alzheimer's Disease measure);   ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory);   CSI (Caregiver Strain Index)
9 Recruiting Nuedexta in Treatment-Resistant Major Depression
Conditions: Major Depressive Disorder;   Treatment Resistant
Intervention: Drug: dextromethorphan/quinidine
Outcome Measures: Change in Montgomery-Asberg Depression Rating Scale;   Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form;   Change in Range of Impaired Functioning Tool;   Change in Sheehan Disability Scale;   Patient Rated Inventory of Side Effects (PRISE);   Columbia-Suicide Severity Rating Scale (C-SSRS);   Quick Inventory of Depressive Symptomatology, Self Report (QIDS-SR);   Clinical Global Impression (CGI) scale;   Change in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)
10 Unknown  Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome
Condition: Rett Syndrome
Interventions: Drug: dextromethorphan;   Drug: donepezil hydrochloride
Outcome Measure:
11 Unknown  Combined Therapy of Methadone and Dextromethrophan
Condition: Opioid Abuse
Intervention: Drug: Dextromethorphan
Outcome Measures: Urinary examination;   cytokines
12 Not yet recruiting Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Condition: Depressive Disorder, Treatment-Resistant
Interventions: Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination);   Drug: Placebo
Outcome Measures: Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score;   17-item Hamilton Rating Scale for Depression (HAM-D17);   Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ);   16-item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16);   Sheehan Disability Scale (SDS);   Clinical Global Impression of Severity of Illness (CGI-S);   Clinical Global Impression of Change (CGI-C);   EuroQOL 5 Dimension 5 Level (EQ-5D-5L);   Patient Global Impression of Change (PGIC);   7-item Generalized Anxiety Disorder (GAD-7)
13 Recruiting Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Conditions: Alzheimer's Disease;   Pseudobulbar Affect (PBA)
Intervention: Drug: Nuedexta (20/10)
Outcome Measures: reduction of PBA frequency;   reduction of PBA severity
14 Recruiting Nuedexta for the Treatment of Adults With Autism
Condition: Autism
Intervention: Drug: Nuedexta
Outcome Measures: Reduction in Maladaptive Behaviors;   Reduction in Aggressive Behavior;   Safety and Tolerability
15 Recruiting Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Conditions: Pseudobulbar Affect (PBA);   Stroke;   Dementia;   Traumatic Brain Injury (TBI)
Intervention: Drug: Nuedexta (DM 20 mg/Q 10 mg)
Outcome Measures: The primary efficacy endpoint is the mean change from baseline at 12 weeks in CNS-LS score.;   Safety and Tolerability;   PBA Episode Counts;   Patient Global Impression-Change (PGI-C);   Clinical Global Impression-Change (CGI-C);   Patient Satisfaction with Treatment Survey
16 Recruiting FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Condition: Lung Cancer
Interventions: Drug: DOTAP:Chol-fus1;   Drug: Erlotinib;   Drug: Dexamethasone;   Drug: Diphenhydramine
Outcome Measures: Maximum Tolerated Dose (MTD) Level for Drug Treatment Combination;   Response Rate
17 Unknown  Safety and Efficacy Study of Single Port Laparoscopic Appendectomy in Acute Appendicitis
Condition: Appendicitis
Interventions: Procedure: Single port laparoscopic appendectomy;   Procedure: 3 port laparoscopic appendectomy
Outcome Measures: Safety;   Efficacy
18 Recruiting Effects of Hallucinogens and Other Drugs on Mood and Performance
Condition: Healthy
Intervention: Drug: Hallucinogens and psychoactive substances
Outcome Measures: Rating of "Drug Liking" on the End of Day Questionnaire;   Hallucinogen Rating Scale

These studies may lead to new treatments and are adding insight into Theraflu etiology and treatment.

A major focus of Theraflu research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Theraflu